Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial Article Swipe
Hana M. El Sahly
,
Lindsey R. Baden
,
Brandon Essink
,
David C. Montefiori
,
Adrian McDermont
,
Richard Rupp
,
Michael Lewis
,
Shobha Swaminathan
,
Carl Griffin
,
Veronica Fragoso
,
Vicki E. Miller
,
Bethany Girard
,
Yamuna Devi Paila
,
Weiping Deng
,
Joanne E. Tomassini
,
Robert Paris
,
F. Schödel
,
Rituparna Das
,
Allison August
,
Brett Leav
,
Jacqueline M. Miller
,
Haiyu Zhou
,
Rolando Pajón
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/infdis/jiac188
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1093/infdis/jiac188
Background Messenger RNA (mRNA)–1273 vaccine demonstrated 93.2% efficacy against coronavirus disease 2019 (COVID-19) in the Coronavirus Efficacy (COVE) trial. The humoral immunogenicity results are now reported. Methods Participants received 2 mRNA-1273 (100 µg) or placebo injections, 28 days apart. Immune responses were evaluated in a prespecified, randomly selected per-protocol immunogenicity population (n = 272 placebo; n = 1185 mRNA-1273). Serum binding antibodies (bAbs) and neutralizing antibodies (nAbs) to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–spike protein were assessed at days 1, 29, and 57 by baseline SARS-CoV-2–negative (n = 1197) and SARS-CoV-2–positive (n = 260) status, age, and sex. Results SARS-CoV-2–negative vaccinees had bAb geometric mean AU/mL levels of 35 753 at day 29 that increased to 316 448 at day 57 and nAb inhibitory dilution 50% titers of 55 at day 29 that rose to 1081 at day 57. In SARS-CoV-2–positive vacinees, the first mRNA-1273 injection elicited bAb and nAb levels that were 11-fold (410 049) and 27-fold (1479) higher than in SARS-CoV-2–negative vaccinees, respectively, and were comparable to levels after 2 injections in uninfected participants. Findings were generally consistent by age and sex. Conclusions mRNA-1273 elicited robust serologic immune responses across age, sex, and SARS-CoV-2 status, consistent with its high COVID-19 efficacy. Higher immune responses in those previously infected support a booster-type effect. Clinical Trials Registration. NCT04470427.
Related Topics
Concepts
Immunogenicity
Medicine
Placebo
Immune system
Neutralizing antibody
Antibody
Immunology
Coronavirus
Serology
Titer
Internal medicine
Virology
Coronavirus disease 2019 (COVID-19)
Disease
Infectious disease (medical specialty)
Pathology
Alternative medicine
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1093/infdis/jiac188
- OA Status
- green
- Cited By
- 17
- References
- 43
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4280543769
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4280543769Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1093/infdis/jiac188Digital Object Identifier
- Title
-
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) TrialWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-05-06Full publication date if available
- Authors
-
Hana M. El Sahly, Lindsey R. Baden, Brandon Essink, David C. Montefiori, Adrian McDermont, Richard Rupp, Michael Lewis, Shobha Swaminathan, Carl Griffin, Veronica Fragoso, Vicki E. Miller, Bethany Girard, Yamuna Devi Paila, Weiping Deng, Joanne E. Tomassini, Robert Paris, F. Schödel, Rituparna Das, Allison August, Brett Leav, Jacqueline M. Miller, Haiyu Zhou, Rolando PajónList of authors in order
- Landing page
-
https://doi.org/10.1093/infdis/jiac188Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/9213865Direct OA link when available
- Concepts
-
Immunogenicity, Medicine, Placebo, Immune system, Neutralizing antibody, Antibody, Immunology, Coronavirus, Serology, Titer, Internal medicine, Virology, Coronavirus disease 2019 (COVID-19), Disease, Infectious disease (medical specialty), Pathology, Alternative medicineTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
17Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 3, 2024: 6, 2023: 4, 2022: 4Per-year citation counts (last 5 years)
- References (count)
-
43Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4280543769 |
|---|---|
| doi | https://doi.org/10.1093/infdis/jiac188 |
| ids.doi | https://doi.org/10.1093/infdis/jiac188 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35535503 |
| ids.openalex | https://openalex.org/W4280543769 |
| fwci | 2.12809052 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D006801 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Humans |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000090983 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | 2019-nCoV Vaccine mRNA-1273 |
| mesh[2].qualifier_ui | |
| mesh[2].descriptor_ui | D057134 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | |
| mesh[2].descriptor_name | Antibodies, Neutralizing |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D000914 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | Antibodies, Viral |
| mesh[4].qualifier_ui | Q000517 |
| mesh[4].descriptor_ui | D000086382 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | prevention & control |
| mesh[4].descriptor_name | COVID-19 |
| mesh[5].qualifier_ui | |
| mesh[5].descriptor_ui | D000086663 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | |
| mesh[5].descriptor_name | COVID-19 Vaccines |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D000071497 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Immunogenicity, Vaccine |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D012333 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | RNA, Messenger |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D000086402 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | SARS-CoV-2 |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D064370 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Spike Glycoprotein, Coronavirus |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D006801 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | Humans |
| mesh[11].qualifier_ui | |
| mesh[11].descriptor_ui | D000090983 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | |
| mesh[11].descriptor_name | 2019-nCoV Vaccine mRNA-1273 |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D057134 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Antibodies, Neutralizing |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000914 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | Antibodies, Viral |
| mesh[14].qualifier_ui | Q000517 |
| mesh[14].descriptor_ui | D000086382 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | prevention & control |
| mesh[14].descriptor_name | COVID-19 |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D000086663 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | COVID-19 Vaccines |
| mesh[16].qualifier_ui | |
| mesh[16].descriptor_ui | D000071497 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | |
| mesh[16].descriptor_name | Immunogenicity, Vaccine |
| mesh[17].qualifier_ui | |
| mesh[17].descriptor_ui | D012333 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | |
| mesh[17].descriptor_name | RNA, Messenger |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D000086402 |
| mesh[18].is_major_topic | True |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | SARS-CoV-2 |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D064370 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Spike Glycoprotein, Coronavirus |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D006801 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Humans |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D000090983 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | 2019-nCoV Vaccine mRNA-1273 |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D057134 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Antibodies, Neutralizing |
| mesh[23].qualifier_ui | |
| mesh[23].descriptor_ui | D000914 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | |
| mesh[23].descriptor_name | Antibodies, Viral |
| mesh[24].qualifier_ui | Q000517 |
| mesh[24].descriptor_ui | D000086382 |
| mesh[24].is_major_topic | True |
| mesh[24].qualifier_name | prevention & control |
| mesh[24].descriptor_name | COVID-19 |
| mesh[25].qualifier_ui | |
| mesh[25].descriptor_ui | D000086663 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | |
| mesh[25].descriptor_name | COVID-19 Vaccines |
| mesh[26].qualifier_ui | |
| mesh[26].descriptor_ui | D000071497 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | |
| mesh[26].descriptor_name | Immunogenicity, Vaccine |
| mesh[27].qualifier_ui | |
| mesh[27].descriptor_ui | D012333 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | |
| mesh[27].descriptor_name | RNA, Messenger |
| mesh[28].qualifier_ui | |
| mesh[28].descriptor_ui | D000086402 |
| mesh[28].is_major_topic | True |
| mesh[28].qualifier_name | |
| mesh[28].descriptor_name | SARS-CoV-2 |
| mesh[29].qualifier_ui | |
| mesh[29].descriptor_ui | D064370 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | |
| mesh[29].descriptor_name | Spike Glycoprotein, Coronavirus |
| mesh[30].qualifier_ui | |
| mesh[30].descriptor_ui | D006801 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | |
| mesh[30].descriptor_name | Humans |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D000090983 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | 2019-nCoV Vaccine mRNA-1273 |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D057134 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Antibodies, Neutralizing |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D000914 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Antibodies, Viral |
| mesh[34].qualifier_ui | Q000517 |
| mesh[34].descriptor_ui | D000086382 |
| mesh[34].is_major_topic | True |
| mesh[34].qualifier_name | prevention & control |
| mesh[34].descriptor_name | COVID-19 |
| mesh[35].qualifier_ui | |
| mesh[35].descriptor_ui | D000086663 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | |
| mesh[35].descriptor_name | COVID-19 Vaccines |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D000071497 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Immunogenicity, Vaccine |
| mesh[37].qualifier_ui | |
| mesh[37].descriptor_ui | D012333 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | |
| mesh[37].descriptor_name | RNA, Messenger |
| mesh[38].qualifier_ui | |
| mesh[38].descriptor_ui | D000086402 |
| mesh[38].is_major_topic | True |
| mesh[38].qualifier_name | |
| mesh[38].descriptor_name | SARS-CoV-2 |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D064370 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Spike Glycoprotein, Coronavirus |
| mesh[40].qualifier_ui | |
| mesh[40].descriptor_ui | D006801 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | |
| mesh[40].descriptor_name | Humans |
| mesh[41].qualifier_ui | |
| mesh[41].descriptor_ui | D000090983 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | |
| mesh[41].descriptor_name | 2019-nCoV Vaccine mRNA-1273 |
| mesh[42].qualifier_ui | |
| mesh[42].descriptor_ui | D057134 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | |
| mesh[42].descriptor_name | Antibodies, Neutralizing |
| mesh[43].qualifier_ui | |
| mesh[43].descriptor_ui | D000914 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | |
| mesh[43].descriptor_name | Antibodies, Viral |
| mesh[44].qualifier_ui | Q000517 |
| mesh[44].descriptor_ui | D000086382 |
| mesh[44].is_major_topic | True |
| mesh[44].qualifier_name | prevention & control |
| mesh[44].descriptor_name | COVID-19 |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D000086663 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | COVID-19 Vaccines |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D000071497 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Immunogenicity, Vaccine |
| mesh[47].qualifier_ui | |
| mesh[47].descriptor_ui | D012333 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | |
| mesh[47].descriptor_name | RNA, Messenger |
| mesh[48].qualifier_ui | |
| mesh[48].descriptor_ui | D000086402 |
| mesh[48].is_major_topic | True |
| mesh[48].qualifier_name | |
| mesh[48].descriptor_name | SARS-CoV-2 |
| mesh[49].qualifier_ui | |
| mesh[49].descriptor_ui | D064370 |
| mesh[49].is_major_topic | False |
| mesh[49].qualifier_name | |
| mesh[49].descriptor_name | Spike Glycoprotein, Coronavirus |
| type | article |
| title | Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial |
| biblio.issue | 10 |
| biblio.volume | 226 |
| biblio.last_page | 1742 |
| biblio.first_page | 1731 |
| grants[0].funder | https://openalex.org/F4320337355 |
| grants[0].award_id | |
| grants[0].funder_display_name | National Institute of Allergy and Infectious Diseases |
| topics[0].id | https://openalex.org/T10118 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2725 |
| topics[0].subfield.display_name | Infectious Diseases |
| topics[0].display_name | SARS-CoV-2 and COVID-19 Research |
| topics[1].id | https://openalex.org/T11495 |
| topics[1].field.id | https://openalex.org/fields/11 |
| topics[1].field.display_name | Agricultural and Biological Sciences |
| topics[1].score | 0.993399977684021 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/1103 |
| topics[1].subfield.display_name | Animal Science and Zoology |
| topics[1].display_name | Animal Virus Infections Studies |
| topics[2].id | https://openalex.org/T10976 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9918000102043152 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2725 |
| topics[2].subfield.display_name | Infectious Diseases |
| topics[2].display_name | Viral gastroenteritis research and epidemiology |
| funders[0].id | https://openalex.org/F4320337355 |
| funders[0].ror | https://ror.org/043z4tv69 |
| funders[0].display_name | National Institute of Allergy and Infectious Diseases |
| is_xpac | False |
| apc_list.value | 4320 |
| apc_list.currency | USD |
| apc_list.value_usd | 4320 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2780868878 |
| concepts[0].level | 3 |
| concepts[0].score | 0.8742503523826599 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1660197 |
| concepts[0].display_name | Immunogenicity |
| concepts[1].id | https://openalex.org/C71924100 |
| concepts[1].level | 0 |
| concepts[1].score | 0.6729650497436523 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[1].display_name | Medicine |
| concepts[2].id | https://openalex.org/C27081682 |
| concepts[2].level | 3 |
| concepts[2].score | 0.6168287396430969 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q269829 |
| concepts[2].display_name | Placebo |
| concepts[3].id | https://openalex.org/C8891405 |
| concepts[3].level | 2 |
| concepts[3].score | 0.5892772078514099 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[3].display_name | Immune system |
| concepts[4].id | https://openalex.org/C2779261636 |
| concepts[4].level | 3 |
| concepts[4].score | 0.573120653629303 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q7003054 |
| concepts[4].display_name | Neutralizing antibody |
| concepts[5].id | https://openalex.org/C159654299 |
| concepts[5].level | 2 |
| concepts[5].score | 0.5452216267585754 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[5].display_name | Antibody |
| concepts[6].id | https://openalex.org/C203014093 |
| concepts[6].level | 1 |
| concepts[6].score | 0.5116856098175049 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[6].display_name | Immunology |
| concepts[7].id | https://openalex.org/C2777648638 |
| concepts[7].level | 5 |
| concepts[7].score | 0.5092521905899048 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q57751738 |
| concepts[7].display_name | Coronavirus |
| concepts[8].id | https://openalex.org/C45189115 |
| concepts[8].level | 3 |
| concepts[8].score | 0.48031964898109436 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q502159 |
| concepts[8].display_name | Serology |
| concepts[9].id | https://openalex.org/C32611913 |
| concepts[9].level | 3 |
| concepts[9].score | 0.43196019530296326 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[9].display_name | Titer |
| concepts[10].id | https://openalex.org/C126322002 |
| concepts[10].level | 1 |
| concepts[10].score | 0.37018537521362305 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[10].display_name | Internal medicine |
| concepts[11].id | https://openalex.org/C159047783 |
| concepts[11].level | 1 |
| concepts[11].score | 0.35961341857910156 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7215 |
| concepts[11].display_name | Virology |
| concepts[12].id | https://openalex.org/C3008058167 |
| concepts[12].level | 4 |
| concepts[12].score | 0.30160731077194214 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q84263196 |
| concepts[12].display_name | Coronavirus disease 2019 (COVID-19) |
| concepts[13].id | https://openalex.org/C2779134260 |
| concepts[13].level | 2 |
| concepts[13].score | 0.14915677905082703 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[13].display_name | Disease |
| concepts[14].id | https://openalex.org/C524204448 |
| concepts[14].level | 3 |
| concepts[14].score | 0.09471306204795837 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q788926 |
| concepts[14].display_name | Infectious disease (medical specialty) |
| concepts[15].id | https://openalex.org/C142724271 |
| concepts[15].level | 1 |
| concepts[15].score | 0.06596803665161133 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[15].display_name | Pathology |
| concepts[16].id | https://openalex.org/C204787440 |
| concepts[16].level | 2 |
| concepts[16].score | 0.0 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q188504 |
| concepts[16].display_name | Alternative medicine |
| keywords[0].id | https://openalex.org/keywords/immunogenicity |
| keywords[0].score | 0.8742503523826599 |
| keywords[0].display_name | Immunogenicity |
| keywords[1].id | https://openalex.org/keywords/medicine |
| keywords[1].score | 0.6729650497436523 |
| keywords[1].display_name | Medicine |
| keywords[2].id | https://openalex.org/keywords/placebo |
| keywords[2].score | 0.6168287396430969 |
| keywords[2].display_name | Placebo |
| keywords[3].id | https://openalex.org/keywords/immune-system |
| keywords[3].score | 0.5892772078514099 |
| keywords[3].display_name | Immune system |
| keywords[4].id | https://openalex.org/keywords/neutralizing-antibody |
| keywords[4].score | 0.573120653629303 |
| keywords[4].display_name | Neutralizing antibody |
| keywords[5].id | https://openalex.org/keywords/antibody |
| keywords[5].score | 0.5452216267585754 |
| keywords[5].display_name | Antibody |
| keywords[6].id | https://openalex.org/keywords/immunology |
| keywords[6].score | 0.5116856098175049 |
| keywords[6].display_name | Immunology |
| keywords[7].id | https://openalex.org/keywords/coronavirus |
| keywords[7].score | 0.5092521905899048 |
| keywords[7].display_name | Coronavirus |
| keywords[8].id | https://openalex.org/keywords/serology |
| keywords[8].score | 0.48031964898109436 |
| keywords[8].display_name | Serology |
| keywords[9].id | https://openalex.org/keywords/titer |
| keywords[9].score | 0.43196019530296326 |
| keywords[9].display_name | Titer |
| keywords[10].id | https://openalex.org/keywords/internal-medicine |
| keywords[10].score | 0.37018537521362305 |
| keywords[10].display_name | Internal medicine |
| keywords[11].id | https://openalex.org/keywords/virology |
| keywords[11].score | 0.35961341857910156 |
| keywords[11].display_name | Virology |
| keywords[12].id | https://openalex.org/keywords/coronavirus-disease-2019 |
| keywords[12].score | 0.30160731077194214 |
| keywords[12].display_name | Coronavirus disease 2019 (COVID-19) |
| keywords[13].id | https://openalex.org/keywords/disease |
| keywords[13].score | 0.14915677905082703 |
| keywords[13].display_name | Disease |
| keywords[14].id | https://openalex.org/keywords/infectious-disease |
| keywords[14].score | 0.09471306204795837 |
| keywords[14].display_name | Infectious disease (medical specialty) |
| keywords[15].id | https://openalex.org/keywords/pathology |
| keywords[15].score | 0.06596803665161133 |
| keywords[15].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.1093/infdis/jiac188 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S54542293 |
| locations[0].source.issn | 0022-1899, 1537-6613 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0022-1899 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | The Journal of Infectious Diseases |
| locations[0].source.host_organization | https://openalex.org/P4310311648 |
| locations[0].source.host_organization_name | Oxford University Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310311648 |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | The Journal of Infectious Diseases |
| locations[0].landing_page_url | https://doi.org/10.1093/infdis/jiac188 |
| locations[1].id | pmid:35535503 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | The Journal of infectious diseases |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35535503 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:9213865 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | other-oa |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/other-oa |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | J Infect Dis |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9213865 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5025421448 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-0489-0074 |
| authorships[0].author.display_name | Hana M. El Sahly |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I181547552 |
| authorships[0].affiliations[0].raw_affiliation_string | Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas , USA |
| authorships[0].institutions[0].id | https://openalex.org/I181547552 |
| authorships[0].institutions[0].ror | https://ror.org/02pttbw34 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I181547552, https://openalex.org/I2801539370 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Baylor College of Medicine |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Hana M El Sahly |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Molecular Virology and Microbiology, Baylor College of Medicine , Houston, Texas , USA |
| authorships[1].author.id | https://openalex.org/A5091029647 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Lindsey R. Baden |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I1283280774 |
| authorships[1].affiliations[0].raw_affiliation_string | Division of Infectious Diseases, Brigham and Women’s Hospital , Boston, Massachusetts , USA |
| authorships[1].institutions[0].id | https://openalex.org/I1283280774 |
| authorships[1].institutions[0].ror | https://ror.org/04b6nzv94 |
| authorships[1].institutions[0].type | healthcare |
| authorships[1].institutions[0].lineage | https://openalex.org/I1283280774, https://openalex.org/I48633490 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Brigham and Women's Hospital |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Lindsey R Baden |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Division of Infectious Diseases, Brigham and Women’s Hospital , Boston, Massachusetts , USA |
| authorships[2].author.id | https://openalex.org/A5114022030 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-7309-228X |
| authorships[2].author.display_name | Brandon Essink |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I4210140301 |
| authorships[2].affiliations[0].raw_affiliation_string | Meridian Clinical Research , Omaha, Nebraska , USA |
| authorships[2].institutions[0].id | https://openalex.org/I4210140301 |
| authorships[2].institutions[0].ror | https://ror.org/03hgnab62 |
| authorships[2].institutions[0].type | facility |
| authorships[2].institutions[0].lineage | https://openalex.org/I4210140301 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Meridian Clinical Research |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Brandon Essink |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Meridian Clinical Research , Omaha, Nebraska , USA |
| authorships[3].author.id | https://openalex.org/A5004036928 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-0856-6319 |
| authorships[3].author.display_name | David C. Montefiori |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I4210126298 |
| authorships[3].affiliations[0].raw_affiliation_string | Immune Assay Team, Department of Surgery, Duke University Medical Center , Durham, North Carolina , USA |
| authorships[3].institutions[0].id | https://openalex.org/I4210126298 |
| authorships[3].institutions[0].ror | https://ror.org/03njmea73 |
| authorships[3].institutions[0].type | healthcare |
| authorships[3].institutions[0].lineage | https://openalex.org/I4210126298, https://openalex.org/I4210144876 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Duke Medical Center |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | David Montefiori |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Immune Assay Team, Department of Surgery, Duke University Medical Center , Durham, North Carolina , USA |
| authorships[4].author.id | https://openalex.org/A5071164172 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Adrian McDermont |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[4].affiliations[0].raw_affiliation_string | Vaccine Research Center, National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland , USA |
| authorships[4].institutions[0].id | https://openalex.org/I4210134534 |
| authorships[4].institutions[0].ror | https://ror.org/043z4tv69 |
| authorships[4].institutions[0].type | facility |
| authorships[4].institutions[0].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238, https://openalex.org/I4210134534 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | National Institute of Allergy and Infectious Diseases |
| authorships[4].institutions[1].id | https://openalex.org/I1299303238 |
| authorships[4].institutions[1].ror | https://ror.org/01cwqze88 |
| authorships[4].institutions[1].type | government |
| authorships[4].institutions[1].lineage | https://openalex.org/I1299022934, https://openalex.org/I1299303238 |
| authorships[4].institutions[1].country_code | US |
| authorships[4].institutions[1].display_name | National Institutes of Health |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Adrian McDermont |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Vaccine Research Center, National Institutes of Health, National Institute of Allergy and Infectious Diseases , Bethesda, Maryland , USA |
| authorships[5].author.id | https://openalex.org/A5052872357 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-9659-1217 |
| authorships[5].author.display_name | Richard Rupp |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I55302922 |
| authorships[5].affiliations[0].raw_affiliation_string | Sealy Institute for Vaccine Sciences, University of Texas Medical Branch , Galveston, Texas , USA |
| authorships[5].institutions[0].id | https://openalex.org/I55302922 |
| authorships[5].institutions[0].ror | https://ror.org/016tfm930 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I55302922 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | The University of Texas Medical Branch at Galveston |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Richard Rupp |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Sealy Institute for Vaccine Sciences, University of Texas Medical Branch , Galveston, Texas , USA |
| authorships[6].author.id | https://openalex.org/A5113559406 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Michael Lewis |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210156876 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Pathology, Veterans Affairs Greater Los Angeles Healthcare , Los Angeles, California , USA |
| authorships[6].institutions[0].id | https://openalex.org/I4210156876 |
| authorships[6].institutions[0].ror | https://ror.org/05xcarb80 |
| authorships[6].institutions[0].type | healthcare |
| authorships[6].institutions[0].lineage | https://openalex.org/I1322918889, https://openalex.org/I2799886695, https://openalex.org/I4210138663, https://openalex.org/I4210156876 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | VA Greater Los Angeles Healthcare System |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Michael Lewis |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Pathology, Veterans Affairs Greater Los Angeles Healthcare , Los Angeles, California , USA |
| authorships[7].author.id | https://openalex.org/A5039731539 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8609-3073 |
| authorships[7].author.display_name | Shobha Swaminathan |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I102322142, https://openalex.org/I4402554120 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Medicine, Rutgers, New Jersey Medical School , Newark, New Jersey , USA |
| authorships[7].institutions[0].id | https://openalex.org/I4402554120 |
| authorships[7].institutions[0].ror | https://ror.org/014ye1258 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I102322142, https://openalex.org/I4390039302, https://openalex.org/I4402554120 |
| authorships[7].institutions[0].country_code | |
| authorships[7].institutions[0].display_name | Rutgers New Jersey Medical School |
| authorships[7].institutions[1].id | https://openalex.org/I102322142 |
| authorships[7].institutions[1].ror | https://ror.org/05vt9qd57 |
| authorships[7].institutions[1].type | education |
| authorships[7].institutions[1].lineage | https://openalex.org/I102322142 |
| authorships[7].institutions[1].country_code | US |
| authorships[7].institutions[1].display_name | Rutgers, The State University of New Jersey |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Shobha Swaminathan |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Medicine, Rutgers, New Jersey Medical School , Newark, New Jersey , USA |
| authorships[8].author.id | https://openalex.org/A5008908371 |
| authorships[8].author.orcid | |
| authorships[8].author.display_name | Carl Griffin |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I149530613, https://openalex.org/I4210136621 |
| authorships[8].affiliations[0].raw_affiliation_string | Lynn Health Science Institute , Oklahoma City, Oklahoma , USA |
| authorships[8].institutions[0].id | https://openalex.org/I4210136621 |
| authorships[8].institutions[0].ror | https://ror.org/02vfnsn98 |
| authorships[8].institutions[0].type | other |
| authorships[8].institutions[0].lineage | https://openalex.org/I4210136621 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Lynn Health Science Institute |
| authorships[8].institutions[1].id | https://openalex.org/I149530613 |
| authorships[8].institutions[1].ror | https://ror.org/04nqv0v23 |
| authorships[8].institutions[1].type | education |
| authorships[8].institutions[1].lineage | https://openalex.org/I149530613 |
| authorships[8].institutions[1].country_code | US |
| authorships[8].institutions[1].display_name | Lynn University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Carl Griffin |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Lynn Health Science Institute , Oklahoma City, Oklahoma , USA |
| authorships[9].author.id | https://openalex.org/A5087407428 |
| authorships[9].author.orcid | |
| authorships[9].author.display_name | Veronica Fragoso |
| authorships[9].affiliations[0].raw_affiliation_string | Texas Center for Drug Development, DM Clinical Research , Houston, Texas , USA |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Veronica Fragoso |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Texas Center for Drug Development, DM Clinical Research , Houston, Texas , USA |
| authorships[10].author.id | https://openalex.org/A5023704340 |
| authorships[10].author.orcid | |
| authorships[10].author.display_name | Vicki E. Miller |
| authorships[10].affiliations[0].raw_affiliation_string | Texas Center for Drug Development, DM Clinical Research , Tomball, Texas , USA |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Vicki E Miller |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Texas Center for Drug Development, DM Clinical Research , Tomball, Texas , USA |
| authorships[11].author.id | https://openalex.org/A5011395355 |
| authorships[11].author.orcid | https://orcid.org/0000-0001-9390-230X |
| authorships[11].author.display_name | Bethany Girard |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[11].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[11].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[11].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[11].institutions[0].type | company |
| authorships[11].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Bethany Girard |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[12].author.id | https://openalex.org/A5039188670 |
| authorships[12].author.orcid | |
| authorships[12].author.display_name | Yamuna Devi Paila |
| authorships[12].countries | US |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[12].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[12].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[12].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[12].institutions[0].type | company |
| authorships[12].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[12].institutions[0].country_code | US |
| authorships[12].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Yamuna D Paila |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[13].author.id | https://openalex.org/A5000243107 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-9825-3297 |
| authorships[13].author.display_name | Weiping Deng |
| authorships[13].countries | US |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[13].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[13].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[13].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[13].institutions[0].type | company |
| authorships[13].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[13].institutions[0].country_code | US |
| authorships[13].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[13].author_position | middle |
| authorships[13].raw_author_name | Weiping Deng |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[14].author.id | https://openalex.org/A5040420889 |
| authorships[14].author.orcid | https://orcid.org/0000-0002-9399-2867 |
| authorships[14].author.display_name | Joanne E. Tomassini |
| authorships[14].countries | US |
| authorships[14].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[14].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[14].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[14].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[14].institutions[0].type | company |
| authorships[14].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[14].institutions[0].country_code | US |
| authorships[14].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[14].author_position | middle |
| authorships[14].raw_author_name | Joanne E Tomassini |
| authorships[14].is_corresponding | False |
| authorships[14].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[15].author.id | https://openalex.org/A5076243921 |
| authorships[15].author.orcid | https://orcid.org/0000-0003-3234-5989 |
| authorships[15].author.display_name | Robert Paris |
| authorships[15].countries | US |
| authorships[15].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[15].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[15].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[15].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[15].institutions[0].type | company |
| authorships[15].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[15].institutions[0].country_code | US |
| authorships[15].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[15].author_position | middle |
| authorships[15].raw_author_name | Robert Paris |
| authorships[15].is_corresponding | False |
| authorships[15].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[16].author.id | https://openalex.org/A5088924940 |
| authorships[16].author.orcid | https://orcid.org/0000-0002-4059-6289 |
| authorships[16].author.display_name | F. Schödel |
| authorships[16].countries | US |
| authorships[16].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[16].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[16].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[16].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[16].institutions[0].type | company |
| authorships[16].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[16].institutions[0].country_code | US |
| authorships[16].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[16].author_position | middle |
| authorships[16].raw_author_name | Florian Schödel |
| authorships[16].is_corresponding | False |
| authorships[16].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[17].author.id | https://openalex.org/A5101664839 |
| authorships[17].author.orcid | https://orcid.org/0000-0002-5166-0311 |
| authorships[17].author.display_name | Rituparna Das |
| authorships[17].countries | US |
| authorships[17].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[17].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[17].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[17].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[17].institutions[0].type | company |
| authorships[17].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[17].institutions[0].country_code | US |
| authorships[17].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[17].author_position | middle |
| authorships[17].raw_author_name | Rituparna Das |
| authorships[17].is_corresponding | False |
| authorships[17].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[18].author.id | https://openalex.org/A5063402177 |
| authorships[18].author.orcid | https://orcid.org/0000-0002-8668-5252 |
| authorships[18].author.display_name | Allison August |
| authorships[18].countries | US |
| authorships[18].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[18].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[18].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[18].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[18].institutions[0].type | company |
| authorships[18].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[18].institutions[0].country_code | US |
| authorships[18].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[18].author_position | middle |
| authorships[18].raw_author_name | Allison August |
| authorships[18].is_corresponding | False |
| authorships[18].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[19].author.id | https://openalex.org/A5064664004 |
| authorships[19].author.orcid | https://orcid.org/0000-0003-0907-0817 |
| authorships[19].author.display_name | Brett Leav |
| authorships[19].countries | US |
| authorships[19].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[19].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[19].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[19].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[19].institutions[0].type | company |
| authorships[19].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[19].institutions[0].country_code | US |
| authorships[19].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[19].author_position | middle |
| authorships[19].raw_author_name | Brett Leav |
| authorships[19].is_corresponding | False |
| authorships[19].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[20].author.id | https://openalex.org/A5060640852 |
| authorships[20].author.orcid | https://orcid.org/0000-0002-7083-2182 |
| authorships[20].author.display_name | Jacqueline M. Miller |
| authorships[20].countries | US |
| authorships[20].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[20].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[20].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[20].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[20].institutions[0].type | company |
| authorships[20].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[20].institutions[0].country_code | US |
| authorships[20].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[20].author_position | middle |
| authorships[20].raw_author_name | Jacqueline M Miller |
| authorships[20].is_corresponding | False |
| authorships[20].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[21].author.id | https://openalex.org/A5016101422 |
| authorships[21].author.orcid | https://orcid.org/0000-0002-3328-6792 |
| authorships[21].author.display_name | Haiyu Zhou |
| authorships[21].countries | US |
| authorships[21].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[21].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[21].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[21].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[21].institutions[0].type | company |
| authorships[21].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[21].institutions[0].country_code | US |
| authorships[21].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[21].author_position | middle |
| authorships[21].raw_author_name | Honghong Zhou |
| authorships[21].is_corresponding | False |
| authorships[21].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[22].author.id | https://openalex.org/A5039671566 |
| authorships[22].author.orcid | https://orcid.org/0000-0002-5155-5079 |
| authorships[22].author.display_name | Rolando Pajón |
| authorships[22].countries | US |
| authorships[22].affiliations[0].institution_ids | https://openalex.org/I4210108601 |
| authorships[22].affiliations[0].raw_affiliation_string | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| authorships[22].institutions[0].id | https://openalex.org/I4210108601 |
| authorships[22].institutions[0].ror | https://ror.org/01xm4wg91 |
| authorships[22].institutions[0].type | company |
| authorships[22].institutions[0].lineage | https://openalex.org/I4210108601 |
| authorships[22].institutions[0].country_code | US |
| authorships[22].institutions[0].display_name | Moderna Therapeutics (United States) |
| authorships[22].author_position | last |
| authorships[22].raw_author_name | Rolando Pajon |
| authorships[22].is_corresponding | True |
| authorships[22].raw_affiliation_strings | Infectious Disease Development, Moderna, Inc. , Cambridge, Massachusetts , USA |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9213865 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2022-05-22T00:00:00 |
| display_name | Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10118 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2725 |
| primary_topic.subfield.display_name | Infectious Diseases |
| primary_topic.display_name | SARS-CoV-2 and COVID-19 Research |
| related_works | https://openalex.org/W2271934434, https://openalex.org/W4385850546, https://openalex.org/W4321792944, https://openalex.org/W1991270129, https://openalex.org/W2374971639, https://openalex.org/W4223505415, https://openalex.org/W3204629868, https://openalex.org/W4386402208, https://openalex.org/W2024078487, https://openalex.org/W4210369265 |
| cited_by_count | 17 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 3 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 6 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 4 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 4 |
| locations_count | 3 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:9213865 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | other-oa |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | https://openalex.org/licenses/other-oa |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | J Infect Dis |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9213865 |
| primary_location.id | doi:10.1093/infdis/jiac188 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S54542293 |
| primary_location.source.issn | 0022-1899, 1537-6613 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0022-1899 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | The Journal of Infectious Diseases |
| primary_location.source.host_organization | https://openalex.org/P4310311648 |
| primary_location.source.host_organization_name | Oxford University Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310311648 |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | The Journal of Infectious Diseases |
| primary_location.landing_page_url | https://doi.org/10.1093/infdis/jiac188 |
| publication_date | 2022-05-06 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W3113734454, https://openalex.org/W3199784607, https://openalex.org/W3217661335, https://openalex.org/W3189261358, https://openalex.org/W3090717270, https://openalex.org/W3128853581, https://openalex.org/W3132479927, https://openalex.org/W3200674187, https://openalex.org/W3189544042, https://openalex.org/W4210617949, https://openalex.org/W3210296082, https://openalex.org/W6807544935, https://openalex.org/W3174017401, https://openalex.org/W3026558549, https://openalex.org/W3189985782, https://openalex.org/W3163785571, https://openalex.org/W3187723563, https://openalex.org/W3108193091, https://openalex.org/W3110542218, https://openalex.org/W3017017672, https://openalex.org/W2990745657, https://openalex.org/W6797910965, https://openalex.org/W3196397911, https://openalex.org/W3205258492, https://openalex.org/W3121008609, https://openalex.org/W3117773316, https://openalex.org/W3119858919, https://openalex.org/W3155262144, https://openalex.org/W4200629697, https://openalex.org/W3127600917, https://openalex.org/W6801975967, https://openalex.org/W4206636604, https://openalex.org/W3036386821, https://openalex.org/W3048117004, https://openalex.org/W3122777490, https://openalex.org/W3141087105, https://openalex.org/W3164002264, https://openalex.org/W3217514210, https://openalex.org/W3183171079, https://openalex.org/W3173992891, https://openalex.org/W4210362857, https://openalex.org/W3202142813, https://openalex.org/W3175391525 |
| referenced_works_count | 43 |
| abstract_inverted_index.2 | 30, 74, 173 |
| abstract_inverted_index.= | 53, 57, 89, 94 |
| abstract_inverted_index.a | 45, 213 |
| abstract_inverted_index.n | 56 |
| abstract_inverted_index.(n | 52, 88, 93 |
| abstract_inverted_index.1, | 81 |
| abstract_inverted_index.28 | 37 |
| abstract_inverted_index.29 | 114, 133 |
| abstract_inverted_index.35 | 110 |
| abstract_inverted_index.55 | 130 |
| abstract_inverted_index.57 | 84, 122 |
| abstract_inverted_index.In | 141 |
| abstract_inverted_index.at | 79, 112, 120, 131, 138 |
| abstract_inverted_index.by | 85, 182 |
| abstract_inverted_index.in | 14, 44, 163, 175, 208 |
| abstract_inverted_index.of | 109, 129 |
| abstract_inverted_index.or | 34 |
| abstract_inverted_index.to | 68, 117, 136, 170 |
| abstract_inverted_index.272 | 54 |
| abstract_inverted_index.29, | 82 |
| abstract_inverted_index.316 | 118 |
| abstract_inverted_index.448 | 119 |
| abstract_inverted_index.50% | 127 |
| abstract_inverted_index.57. | 140 |
| abstract_inverted_index.753 | 111 |
| abstract_inverted_index.RNA | 3 |
| abstract_inverted_index.The | 20 |
| abstract_inverted_index.age | 183 |
| abstract_inverted_index.and | 64, 83, 91, 98, 123, 150, 158, 167, 184, 196 |
| abstract_inverted_index.are | 24 |
| abstract_inverted_index.bAb | 104, 149 |
| abstract_inverted_index.day | 113, 121, 132, 139 |
| abstract_inverted_index.had | 103 |
| abstract_inverted_index.its | 201 |
| abstract_inverted_index.nAb | 124, 151 |
| abstract_inverted_index.now | 25 |
| abstract_inverted_index.the | 15, 144 |
| abstract_inverted_index.(100 | 32 |
| abstract_inverted_index.(410 | 156 |
| abstract_inverted_index.049) | 157 |
| abstract_inverted_index.1081 | 137 |
| abstract_inverted_index.1185 | 58 |
| abstract_inverted_index.2019 | 12 |
| abstract_inverted_index.260) | 95 |
| abstract_inverted_index.age, | 97, 194 |
| abstract_inverted_index.days | 38, 80 |
| abstract_inverted_index.high | 202 |
| abstract_inverted_index.mean | 106 |
| abstract_inverted_index.rose | 135 |
| abstract_inverted_index.sex, | 195 |
| abstract_inverted_index.sex. | 99, 185 |
| abstract_inverted_index.than | 162 |
| abstract_inverted_index.that | 115, 134, 153 |
| abstract_inverted_index.were | 42, 77, 154, 168, 179 |
| abstract_inverted_index.with | 200 |
| abstract_inverted_index.µg) | 33 |
| abstract_inverted_index.1197) | 90 |
| abstract_inverted_index.93.2% | 7 |
| abstract_inverted_index.AU/mL | 107 |
| abstract_inverted_index.Serum | 60 |
| abstract_inverted_index.acute | 70 |
| abstract_inverted_index.after | 172 |
| abstract_inverted_index.first | 145 |
| abstract_inverted_index.those | 209 |
| abstract_inverted_index.(1479) | 160 |
| abstract_inverted_index.(COVE) | 18 |
| abstract_inverted_index.(bAbs) | 63 |
| abstract_inverted_index.(nAbs) | 67 |
| abstract_inverted_index.Higher | 205 |
| abstract_inverted_index.Immune | 40 |
| abstract_inverted_index.Trials | 217 |
| abstract_inverted_index.across | 193 |
| abstract_inverted_index.apart. | 39 |
| abstract_inverted_index.higher | 161 |
| abstract_inverted_index.immune | 191, 206 |
| abstract_inverted_index.levels | 108, 152, 171 |
| abstract_inverted_index.robust | 189 |
| abstract_inverted_index.severe | 69 |
| abstract_inverted_index.titers | 128 |
| abstract_inverted_index.trial. | 19 |
| abstract_inverted_index.11-fold | 155 |
| abstract_inverted_index.27-fold | 159 |
| abstract_inverted_index.Methods | 27 |
| abstract_inverted_index.Results | 100 |
| abstract_inverted_index.against | 9 |
| abstract_inverted_index.binding | 61 |
| abstract_inverted_index.disease | 11 |
| abstract_inverted_index.effect. | 215 |
| abstract_inverted_index.humoral | 21 |
| abstract_inverted_index.placebo | 35 |
| abstract_inverted_index.protein | 76 |
| abstract_inverted_index.results | 23 |
| abstract_inverted_index.status, | 96, 198 |
| abstract_inverted_index.support | 212 |
| abstract_inverted_index.vaccine | 5 |
| abstract_inverted_index.Abstract | 0 |
| abstract_inverted_index.COVID-19 | 203 |
| abstract_inverted_index.Clinical | 216 |
| abstract_inverted_index.Efficacy | 17 |
| abstract_inverted_index.Findings | 178 |
| abstract_inverted_index.assessed | 78 |
| abstract_inverted_index.baseline | 86 |
| abstract_inverted_index.dilution | 126 |
| abstract_inverted_index.efficacy | 8 |
| abstract_inverted_index.elicited | 148, 188 |
| abstract_inverted_index.infected | 211 |
| abstract_inverted_index.placebo; | 55 |
| abstract_inverted_index.randomly | 47 |
| abstract_inverted_index.received | 29 |
| abstract_inverted_index.selected | 48 |
| abstract_inverted_index.syndrome | 72 |
| abstract_inverted_index.Messenger | 2 |
| abstract_inverted_index.efficacy. | 204 |
| abstract_inverted_index.evaluated | 43 |
| abstract_inverted_index.generally | 180 |
| abstract_inverted_index.geometric | 105 |
| abstract_inverted_index.increased | 116 |
| abstract_inverted_index.injection | 147 |
| abstract_inverted_index.mRNA-1273 | 31, 146, 187 |
| abstract_inverted_index.reported. | 26 |
| abstract_inverted_index.responses | 41, 192, 207 |
| abstract_inverted_index.serologic | 190 |
| abstract_inverted_index.vaccinees | 102 |
| abstract_inverted_index.vacinees, | 143 |
| abstract_inverted_index.(COVID-19) | 13 |
| abstract_inverted_index.Background | 1 |
| abstract_inverted_index.SARS-CoV-2 | 197 |
| abstract_inverted_index.antibodies | 62, 66 |
| abstract_inverted_index.comparable | 169 |
| abstract_inverted_index.consistent | 181, 199 |
| abstract_inverted_index.inhibitory | 125 |
| abstract_inverted_index.injections | 174 |
| abstract_inverted_index.population | 51 |
| abstract_inverted_index.previously | 210 |
| abstract_inverted_index.uninfected | 176 |
| abstract_inverted_index.vaccinees, | 165 |
| abstract_inverted_index.Conclusions | 186 |
| abstract_inverted_index.Coronavirus | 16 |
| abstract_inverted_index.coronavirus | 10, 73 |
| abstract_inverted_index.injections, | 36 |
| abstract_inverted_index.mRNA-1273). | 59 |
| abstract_inverted_index.respiratory | 71 |
| abstract_inverted_index.NCT04470427. | 219 |
| abstract_inverted_index.Participants | 28 |
| abstract_inverted_index.booster-type | 214 |
| abstract_inverted_index.demonstrated | 6 |
| abstract_inverted_index.neutralizing | 65 |
| abstract_inverted_index.per-protocol | 49 |
| abstract_inverted_index.(mRNA)–1273 | 4 |
| abstract_inverted_index.Registration. | 218 |
| abstract_inverted_index.participants. | 177 |
| abstract_inverted_index.prespecified, | 46 |
| abstract_inverted_index.respectively, | 166 |
| abstract_inverted_index.immunogenicity | 22, 50 |
| abstract_inverted_index.(SARS-CoV-2)–spike | 75 |
| abstract_inverted_index.SARS-CoV-2–negative | 87, 101, 164 |
| abstract_inverted_index.SARS-CoV-2–positive | 92, 142 |
| cited_by_percentile_year.max | 98 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5039671566 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 23 |
| corresponding_institution_ids | https://openalex.org/I4210108601 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8199999928474426 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.86609558 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |